Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Share-based Compensation (2016 - 2025)

Fortress Biotech has reported Share-based Compensation over the past 13 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.5 million for Q4 2025, down 84.81% from a year ago — trailing twelve months through Dec 2025 was $28.7 million (down 11.9% YoY), and the annual figure for FY2025 was $28.7 million, down 11.89%.
  • Share-based Compensation for Q4 2025 was $2.5 million at Fortress Biotech, down from $3.2 million in the prior quarter.
  • Over the last five years, Share-based Compensation for FBIO hit a ceiling of $16.8 million in Q2 2025 and a floor of $2.5 million in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $4.9 million (2024), compared with a mean of $6.0 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 337.1% in 2024 and later plummeted 84.81% in 2025.
  • Fortress Biotech's Share-based Compensation stood at $7.0 million in 2021, then fell by 21.76% to $5.5 million in 2022, then crashed by 32.73% to $3.7 million in 2023, then skyrocketed by 337.1% to $16.2 million in 2024, then plummeted by 84.81% to $2.5 million in 2025.
  • The last three reported values for Share-based Compensation were $2.5 million (Q4 2025), $3.2 million (Q3 2025), and $16.8 million (Q2 2025) per Business Quant data.